Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system
Among patients with T2D and CAD in the VA healthcare system, evidence-based SGLT2i and GLP1-RA prescription increased over time, but many eligible patients remained untreated. Although SGLT2i prescription did not differ by race, Black versus White Veterans were less likely to receive evidence-based GLP1-RA prescription. Racial disparities in evidence-based cardiovascular drug prescription exist even in a healthcare system with few economic barriers and may be drug class-specific.
Authors
- Stephen W. Waldo (ORCID: https://orcid.org/0000-0003-0678-4873)
- Sridharan Raghavan (ORCID: https://orcid.org/0000-0003-0643-4873)
- Kamal Henderson (ORCID: https://orcid.org/0000-0001-7999-966X)
- David Saxon (ORCID: https://orcid.org/0000-0002-4309-855X)
- Taufiq Salahuddin (ORCID: https://orcid.org/0000-0002-7482-2280)
- Vanessa Richardson (ORCID: https://orcid.org/0000-0002-9267-2351)
- Gregory G. Schwartz (ORCID: https://orcid.org/0000-0003-2954-0695)
- Paul L. Hess (ORCID: https://orcid.org/0000-0002-3022-764X)
- P. Michael Ho (ORCID: https://orcid.org/0000-0002-7775-6266)
- Demetria M Bolden
Institutions
- Colorado School of Public Health (US)
- VA Eastern Colorado Health Care System (US)
- Rocky Mountain MS Center (US)
- University of Colorado Anschutz Medical Campus (US)
- National Patient Safety Foundation (US)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1016/j.ajpc.2025.100966
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29